Relevance to NICE guidance programmes

Relevance to NICE guidance programmes

Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (NICE technology appraisal 273) was referred to NICE for a technology appraisal in July 2012. However, NICE terminated the appraisal in January 2013 and was unable to recommend the use of tadalafil in the NHS for treating symptoms associated with benign prostatic hyperplasia because no evidence submission was received from the manufacturer of the technology.

In May 2010, NICE issued a clinical guideline on the management of lower urinary tract symptoms in men (NICE clinical guideline 97), which has also been incorporated into a NICE pathway on lower urinary tract symptoms in men.